Early indicators of chronic lung disease in preterm infants with respiratory distress syndrome and their inhibition by melatonin

Journal of Pineal Research

Volumn 36, Issue 4, 2004, Pages 250-255

  Gitto, Eloisa ^a   Reiter, Russel J ^b   Amodio, Aurelio ^a   Romeo, Carmelo ^a   Cuzzocrea, Elisabetta ^a   Sabatino, Giuseppe ^c   Buonocore, Giuseppe ^d   Cordaro, Vincenzo ^a   Trimarchi, Giuseppe ^a   Barberi, Ignazio ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF CHIETI   (Italy)

^d UNIVERSITY OF SIENA   (Italy)

Author keywords

Chronic lung disease; Cytokines; Human; Melatonin; Respiratory distress syndrome

Indexed keywords

INDICATOR; INTERLEUKIN 6; INTERLEUKIN 8; MELATONIN; NITRATE; NITRITE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CHRONIC LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MEASUREMENT; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN; SERUM;

ANTIOXIDANTS; CHRONIC DISEASE; CYTOKINES; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; LUNG DISEASES; MELATONIN; PROGNOSIS; RESPIRATORY DISTRESS SYNDROME, NEWBORN;

EID: 11144355886     PISSN: 07423098     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2004.00124.x     Document Type: Article

References (49)

1. ROZYCKI HJ, COMBER PG, HUFF TF. Cytokines and oxygen radicals after hyperoxia in preterm and term alveolar macrophages. Lung Cell Molec Physiol 2002; 282:1222-1228.
2. NORTHWAY W. An introduction to bronchopulmonary dysplasia. Clin Perinatol 1992; 19:489-495.
3. DELEMOS R, COALSON J. The contribution of experimental models to our understanding of the pathogenesis and treatment of bronchopulmonary dysplasia. Clin Perinatol 1992; 19:521-539.
4. ARNON S, GRIGG J, SILVERMAN M. Pulmonary inflammatory cells in ventilated preterm infants: effect of surfactant treatment. Arch Dis Child 1993; 69:44-48.
5. KELLEY J. Cytokines of the lung. Am Rev Respir Dis 1990; 141:765-788.
6. OGDEN BE, MURPHY SA, SAUNDERS GC, PATHAC D, JOHNSON JD. Neonatal lung neutrophils and elastase/proteinase inhibitor imbalance. Am Rev Respir Dis 1984; 130:817-821.
7. ROZYCKI HJ. Bronchoaleolar interleukin-1 beta in infants on day 1 of life. South Med J 1994; 87:991-996.
8. BAGCHI A, VISCARDI RM, TACIAK V, ENSOR JE, MCCREA KA, HASDAY JD. Increased activity of interleukin 6 but not tumor necrosis factor-alpha in lung lavage of premature infants is associated with the development of bronchopulmonary dysplasia. Pediatr Res 1994; 36:244-252.
9. JONSSON B, TULLUS K, BRAUER A, LU Y, NOACK G. Early increase of TNF alpha and IL-6 in tracheobronchial aspirate fluid indicator of subsequent chronic lung disease in preterm infants. Arch Dis Child 1997; 77:198-201.
10. KOTECHA S, CHAN B, AZAM N, SILVERMAN M, SHAW RJ. Increase in interleukin-8 and soluble intercellular adhesion molecule-1 in bronchoalveolar lavage fluid from premature infants who develop chronic lung disease. Arch Dis Child 1995; 72:90-96.
11. ABMAN SH, GROOTHUIS JR. Pathophysiology and treatment of bronchopulmonary dysplasia: current issues. Pediatr Clin North Am 1994; 41:277-315.
12. WINROW VR, WINYARD PG, MORRIS CJ, BLAKE DR. Free radicals in inflammation: second messenger and mediators of destruction. Br Med Bull 1993; 49:507-522.
13. ASIKAINEN TM, RAIVIO KO, SAKSELA M, KINNULA VL. Expression and developmental profile of antioxidant enzymes in human lung and liver. Am J Respir Cell Mol Biol 1998; 19:942-949.
14. TAN DX, HARDELAND R, MANCHESTER LC et al. Mechanistic and comparative studies of melatonin and classic antioxidants in terms of their interactions with the ABTS cation radical. J Pineal Res 2003; 34:249-259.
15. ALLEGRA M, REITER RJ, TAN DX, GENTILE C, TESORIERE L, LIVREA MA. The chemistry of melatonin's interaction with reactive species. J Pineal Res 2003; 34:1-10.
16. CUZZOCREA S, COSTANTINO G, CAPUTI AP. Protective effect of melatonin on cellular energy depletion mediated by peroxynitrite and poly (ADP-ribose) synthetase activation in a non-septic shock model induced by zymosan in the rat. J Pineal Res 1998; 25:78-85.
17. CUZZOCREA S, REITER RJ. Pharmacological actions of melatonin in acute and chronic inflammation. Curr Top Med Chem 2002; 2:153-165.
18. GITTO E, REITER RJ, CORDARO SP et al. Oxidative and inflammatory parameters in respiratory distress syndrome of preterm newborn: beneficial effects of melatonin. Am J Perinatol (in press).
19. FULIA F, GITTO E, CUZZOCREA S et al. Increased levels of malondialdehyde and nitrite/nitrate in the blood of asphyxiated newborns: reduction by melatonin. J Pineal Res 2001; 31:343-349.
20. FITZGERALD DA, MESIANO G, BROSSEAU L, DAVIS GM. Pulmonary outcome in extremely low birth weight infants. Pediatrics 2000; 105:1209-1215.
21. HILLIER SL, MARTIUS RF, KROHN M, KIVIAT N, HOLMES KK, ESCHENBACH DA. A case-control study of chorioamniotic infection and histologic chorioamnionitis in prematurity. N Engl J Med 1988; 319:972-978.
22. PAYNE NR, STEIMBERG SS, ACKERMAN P et al. New prospective studies of the association of Ureoplasma urealyticum colonization and chronic lung disease. Clin Infect Dis 1993; 17(Suppl. 1): S117-S121
23. SPEER CP. Inflammatory mechanisms in neonatal chronic lung disease. Eur J Pediatr 1999; 158 (Suppl. 1): S18-S22
24. STANDIFORD TJ, HUFFNAGLE GB. Cytokines in host defense against pneumonia. J Invest Med 1997; 45:335-345
25. GHEZZI F, GOMEZ R, ROMERO R et al. Elevated interleukin-8 concentrations in amniotic fluid of mothers whose neonates subsequently develop bronchopulmonary dysplasia. Eur J Obstet Gynecol Reprod Biol 1998; 78:5-10.
26. MURCH SH, COSTELOE K., KLEIN NJ, MACDONALD TT. Early production of macrophage inflammatory protein 1 alpha occurs in respiratory distress syndrome and is associated with poor outcome. Pediatr Res 1996; 40:490-497.
27. EHRENKRANZ RA, MERCURIO MR. Bronchopulmonary dysplasia. In: Effective Care of the Newborn Infant. Sinclair JC, Bracken MB eds, Oxford University Press, Oxford, 1992; pp. 399-424.
28. DEATON PR, MCKELLAR CT, CULBRETH R, VEAL CF, COOPER JA. Hyperoxia stimulates interleukin-8 release from alveolar macrophages and U 937 cells: attenuation by dexamethasone. Am J Physiol Lung Cell Mol Physiol 1994; 267:187-192.
29. DEFORCE LE, PRESTON AM, TAKEUCHI E, KENNEY J, BOXER LA, REMICK DG. Regulation of interleukin 8 gene expression by oxidant stress. J Biol Chem 1993; 268:25568-25576.
30. DESMARQUEST P, CHADELAT K, CORROYER S, CAZALS V, CLEMENT A. Effect of hyperoxia on human macrophage cytokine response. Respir Med 1998; 92:951-960.
31. MONCADA S, PALMER RMJ, HIGGS EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991; 43:109-142.
32. REITER RJ, TAN DX, MANCHESTER LC, QI W. Biochemical reactivity of melatonin with reactive oxygen and nitrogen species: a review of the evidence. Cell Biochem Biophys 2001; 34:237-256.
33. HARDELAND R, POEGGELER B, NIEBERGAIL R, ZELOSKO V. Oxidation of melatonin by carbonate radicals and chemiluminescence entitled during pyrrole ring cleavage. J Pineal Res 2003; 34:17-25.
34. TAN DX, CHEN LD, POEGGELER B, MANCHESTER LC, REITER RJ. Melatonin: a potent, endogenous hydroxyl racial scavenger. Endocrine J 1993; 1:57-60.
35. REITER RJ. Melatonin: lowering the high price of free radicals. News Physiol Sci 2000; 15:246-250.
36. TAN DX, MANCHESTER LC, REITER RJ, QI W, KARBOWNIK M, CALVO JR. Significance of melatonin in antioxidative defence system: reactions and products. Biol Signals Recept 2000; 9:137-159.
37. GULCIN I, BUYUKOKUROGLU ME, KUFREVIOGLU OI. Metal chelating and hydrogen peroxide scavenging effects of melatonin. J Pineal Res 2003; 34:278-281.
38. 2-formyl-5-methoxytryptamine. J Pineal Res 2003; 35:131-137.
39. AGOZZINO P, AVELLONE G, BONGIORNO D et al. Melatonin: structural characterization of its non-enzymatic mono-oxygenate metabolite. J Pineal Res 2003; 35:269-275.
40. REITER RJ, TAN DX, OSUNA C, GITTO E. Actions of melatonin in the reduction of oxidative stress: a review. J Biomed Sci 2000; 7:444-458.
41. RODRIQUEZ C, MAYO JC, SAINZ RM et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 2004; 36:1-9.
42. GITTO E, KARBOWNIK M, REITER RJ et al. Effects of melatonin treatment in septic newborns. Pediatr Res 2001; 50:756-760.
43. BAEUERLE PA, RUPEC RA, PAHL HL. Reactive oxygen intermediates as second messages of a general pathogen response. Pathol Biol (Paris) 1996; 44:29-35.
44. JONES C, CAYABYAB R, KWONG K. Undetectable interleukin (IL)-10 and persistent IL-8 expression in early hyaline membrane disease: a possible developmental basis for the predisposition to chronic lung inflammation in preterm newborns. Pediatr Res 1996; 39:966-975.
45. BONIKOS DS, BENSCH KG. Pathogenesis of bronchopulmonary dysplasia. In: Bronchopulmonary Dysplasia. Merritt T, Northway W, Boynton B eds, Blackwell Scientific Publications, Boston, 1988; pp. 33-58.
46. GARLAND JS, BUCK RK, ALLRED EN, LEVITON A. Hypocarbia before surfactant therapy appears to increase bronchopulmonary dysplasia risk in infants with respiratory distress syndrome. Arch Pediatr Adolesc Med 1995; 149:617-622.
47. SMITH CV, WELTY SE. Molecular mechanisms of oxygen-induced lung injury. In: Chronic Lung Disease of Early Infancy: Lung Biology in Health and Diseases. Bland RD, Coalson J, Lenfant C eds, Marcel Dekker, New York, 1999; pp. 749-778.
48. GITTO E, REITER RJ, KARBOWNIK M, TAN DX, BARBERI I. Respiratory distress syndrome in the newborn: role of oxidative stress. Intensive Care Med 2001; 27:1123-1126.
49. GITTO E, REITER RJ, KARBOWNIK M et al. Causes of oxidative stress in the pre and perinatal period. Biol Neonate 2002; 81:146-157.